The estimated Net Worth of Erik Harris is at least $6.36 Milione dollars as of 1 March 2024. Mr Harris owns over 4,768 units of Ultragenyx Pharmaceutical stock worth over $3,783,292 and over the last 5 years he sold RARE stock worth over $1,783,177. In addition, he makes $793,860 as Exec. VP & Chief Commercial Officer at Ultragenyx Pharmaceutical.
Mr has made over 14 trades of the Ultragenyx Pharmaceutical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,768 units of RARE stock worth $256,328 on 1 March 2024.
The largest trade he's ever made was selling 6,000 units of Ultragenyx Pharmaceutical stock on 5 September 2023 worth over $227,760. On average, Mr trades about 1,058 units every 55 days since 2019. As of 1 March 2024 he still owns at least 67,163 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr Harris stock trades at the bottom of the page.
Erik Harris is the Exec. VP & Chief Commercial Officer at Ultragenyx Pharmaceutical.
As the Exec. VP & Chief Commercial Officer of Ultragenyx Pharmaceutical, the total compensation of Mr Harris at Ultragenyx Pharmaceutical is $793,860. There are 9 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
Mr Harris is 51, he's been the Exec. VP & Chief Commercial Officer of Ultragenyx Pharmaceutical since . There are 20 older and 5 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Erik's mailing address filed with the SEC is C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr e Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: